Rymti is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, and paediatric plaque psoriasis
The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
Clobetasol Propionate Foam, 0.05% has an estimated market size of US $ IO million for twelve months ending Dec 2021 according to IQVIA
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
Twelve abstracts and two late-breaking presentations demonstrate AbbVie and Allergan Aesthetics' shared commitment to advancing research across a spectrum of dermatologic conditions and aesthetic indications
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
Second interchangeable biosimilar product approved by agency
Subscribe To Our Newsletter & Stay Updated
